Mozart Therapeutics Shows Disease-Modifying Potential in Phase 1 Trial

Seattle, Washington, USA & Brisbane, Australia – April 23, 2026

Mozart Therapeutics announced positive interim Phase 1b clinical data for its lead candidate MTX-101, demonstrating promising early evidence of disease-modifying potential in adults with Stage 3 Type 1 Diabetes (T1D). The data, presented at the Immunology of Diabetes Society (IDS) Congress 2026, showed selective modulation of immune pathways, improved beta cell function, and reduction of pathogenic T cells, reinforcing MTX-101’s potential as a novel immunotherapy targeting autoimmune disease mechanisms.

Phase 1 Data Demonstrates Immune Modulation and Clinical Impact

The interim results from the Phase 1b study evaluated MTX-101 in adults with Stage 3 T1D and demonstrated selective activation and proliferation of CD8 regulatory T cells (CD8 Tregs), alongside a reduction in pathogenic CD4 and CD8 T cells, which are key drivers of autoimmune destruction in diabetes. These findings provide strong proof-of-mechanism evidence, indicating that the therapy effectively restores immune balance and suppresses disease-causing immune responses.

Importantly, patients receiving higher dose levels of MTX-101 showed a numeric increase or stabilization in C-peptide levels, a critical biomarker of beta cell function and insulin production. This contrasts with typical disease progression, where C-peptide levels decline rapidly, highlighting the therapy’s potential to preserve pancreatic function and slow disease progression.

The safety profile was favorable, with treatment-emergent adverse events reported as mild to moderate and consistent with immunomodulatory therapies, supporting continued clinical development.

First-in-Class Therapy Targets CD8 Treg Network

MTX-101 represents a first-in-class bispecific antibody therapy designed to modulate the CD8 Treg network, a previously underexplored pathway in autoimmune disease treatment. By targeting inhibitory KIR receptors and CD8-expressing regulatory T cells, the therapy aims to restore immune homeostasis and prevent further destruction of insulin-producing beta cells.

This innovative mechanism differentiates MTX-101 from traditional therapies that primarily manage symptoms rather than addressing underlying immune dysfunction. By intervening early in the disease process, the therapy has the potential to halt disease progression and improve long-term outcomes for patients with T1D.

The approach aligns with the growing trend toward precision immunotherapy, where treatments are designed to target specific immune pathways with high specificity and reduced systemic effects.

Advancing Toward Phase 2 Development and Future Impact

Following these encouraging results, Mozart Therapeutics plans to complete the ongoing Phase 1b study and initiate a global Phase 2 clinical trial in early 2027, marking the next step in advancing MTX-101 toward potential regulatory approval.

The development of MTX-101 addresses a significant unmet need in T1D, where current therapies primarily focus on insulin replacement rather than disease modification. By offering a potential immune-modulating treatment that preserves endogenous insulin production, MTX-101 could fundamentally change the treatment paradigm for T1D.

As autoimmune diseases continue to present complex clinical challenges, innovations like MTX-101 highlight the importance of targeted, mechanism-driven therapies. The positive interim data reinforces confidence in Mozart Therapeutics’ platform and its ability to deliver transformative treatments that restore immune balance and improve patient outcomes.

Source: Mozart Therapeutics press release